Entries by Thomas Gabrielczyk

Accelerate development of adoptive cell therapies

The success of any adoptive cell therapy lies in how effectively and selectively engineered immune cells interact and kill cancer cells. Functional phenomics enables insights that can dramatically accelerate the development of next-gen cell therapies. evorion biotechnologies brings functional phenomics to pharma and biotech partners via exclusive access to a unique, proprietary pipeline for in-depth multi-modal analysis of thousands of cell-cell interactions at single-cell resolution.

Aseptic Closed Small-Volume Processing: Today’s Option`s

Small-volume biopharmaceutical processes continue to grow as more biopharmaceutical, cell therapy and gene therapy companies develop products. A 2021 Association for Regenerative Medicine (ARM) report states that there are 1,085 cell, gene and tissue-based therapy developers worldwide. These companies are engaged in many small-volume (<10L) processes including early-stage drug development and autologous therapies.

Let Excelya recruit the right people for the early phase

Early phase clinical trials require expert support, often across many service areas and specialisms. Recruitment for trials can be complicated, with less flexibility and higher costs as you attempt to acquire top talent on a project-only basis. That’s why CROs are becoming increasingly indispensable. CROs offer fully formed, multi-skilled teams ready to go, who you can bring on board as and when needed.

Graphene

Graphene is an allotrope of carbon and the basic structural element of other allotropes such as graphite and carbon nanotubes. It’s one of the lightest materials known and the strongest compound discovered. With its exceptional mechanical stiffness, strength, elasticity, high surface area and outstanding electrical and thermal conductivity, Graphene is ideal for use in electronics, sensors, biomedical technologies, protective coatings, energy and composite applications.

Advancing cancer immunotherapy

Single cell multiomics has the capacity to address key challenges to developing cell and gene therapies, specifically CAR T-cell therapies. Hear how leading cancer immunotherapy researchers are using these approaches for characterizing the leukapheresis and infusion product, studying the evolution of the cell product in vivo, identifying and defining mechanisms of resistance, and discovering next-generation cell therapies.